Search results
Results From The WOW.Com Content Network
In May 2020, Indian Council of Medical Research's (ICMR's) National Institute of Virology approved and provided the virus strains for developing an Indian COVID-19 vaccine. [ 25 ] [ 26 ] In June 2020, the company received permission to conduct Phase I and Phase II human trials of a developmental COVID-19 vaccine codenamed BBV152 , from the ...
On 20 August 2021, India granted emergency authorization to Zydus Cadila's vaccine ZyCoV-D, the world's first DNA plasmid-based COVID-19 vaccine, for patients 12 and older. India granted emergency use approval to the world's first DNA based COVID-19 vaccine, manufactured by for adults and children aged 12 years and above. The vaccine is ...
India's Dr. Reddy's Laboratories is in talks with partners to export domestically made doses of Russia's COVID-19 vaccine, Sputnik, after New Delhi recently approved shipments of other shots, the ...
Vaccine Maitri ("Vaccine Friendship") [1] is a humanitarian initiative undertaken by the Indian government to provide COVID-19 vaccines to countries around the world. [2] The government started providing vaccines from 20 January 2021. As of 21 February 2022, India had delivered around 16.29 crore (162.9 million) doses of vaccines to 96 ...
Dr. Krishna Ella is an Indian scientist and entrepreneur.He is the founder and Executive Chairman of Bharat Biotech. [1] [2] Ella and his company were responsible for developing India's own COVID-19 vaccine, Covaxin, World's 1st clinically proven conjugated Typhoid Vaccine, TypbarTCV and ROTAVAC.
National regulatory authorities have granted full or emergency use authorizations for 40 COVID-19 vaccines.. Ten vaccines have been approved for emergency or full use by at least one stringent regulatory authority recognized by the World Health Organization (WHO): Pfizer–BioNTech, Oxford–AstraZeneca, Sinopharm BIBP, Moderna, Janssen, CoronaVac, Covaxin, Novavax, Convidecia, and Sanofi ...
A new COVID-19 subvariant, known as XBB.1.16 but often called "Arcturus," has progressively become more viral here in the United States, accounting for 10% of infections through late April.
iNCOVACC (codenamed BBV154) [1] is an intranasal COVID-19 vaccine candidate developed by Bharat Biotech, [2] [3] American company Precision Virologics [4] [5] and the Washington University School of Medicine in St Louis, Missouri, United States.